NEW YORK (GenomeWeb News) - Rosetta Genomics today said it generated no first-quarter sales, while its R&D spending climbed 30 percent, and its net loss increased 33 percent year over year.
 
Rosetta, which went public in February, said that R&D spending for the three months ended March 31, 2007, increased to $1.16 million from $886,000 in the year-ago period. R&D accounted for 52 percent of the company’s spending during the quarter.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.